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ABSTRACT Complexes containing plasmid DNA,
transferrin-polylysine conjugates, and polylysine-conjugated
peptides derived from the N-terminal sequence of the influenza
virus hemagglutinin subunit HA-2 have been used for the
transfer of luciferase or -galactosidase marker genes to K562
cells, HeLa cells, and BNL CL.2 hepatocytes. These DNA
complexes mimic the entry of viruses into cells, as they contain
functions for (i) the packaging of the nucleic acid with polyly-
sine, (i) the attachment to the cell and receptor-mediated
endocytosis with transferrin as a ligand, and (Mi) the release
from endosomes by using membrane-disrupting influenza pep-
tides. The presence of these influenza peptide conjugates in the
DNA complexes renders the complexes active in membrane
disruption in a liposome leakage assay and results in a sub-
stantial augmentation of the transferrin-polylysine-mediated
gene transfer.
The high gene-transfer efficiency of viruses has led to the
development of viral vectors in which part of the viral
genome has been replaced by a gene to be introduced into
eukaryotic cells. These recombinant viral vectors such as
adenoviral (1, 2), retroviral (3, 4), vaccinia (5, 6), and
parvoviral (7, 8) vectors have displayed useful gene delivery
properties in a large number of applications. However, these
vectors are limited in their cell tropism, in the size ofthe gene
to be introduced, and in that the introduced DNA must be
compatible with viral replication. Our approach to establish
an efficient gene transfer device is based on the concept of
adopting distinct viral entry functions and combining them in
a modular fashion.
Viruses contain core proteins in their interior that package
their nucleic acid genome into small compact structures. The
surface proteins of many viruses (for instance adenoviruses,
alphaviruses, orthomyxoviruses, or picornaviruses) contain
two further functions essential for the delivery of the viral
genome into the cytoplasm of the target cells: (i) the binding
of the virus particle to a cellular surface receptor that
mediates endocytosis of the virion into endosomes, and (ii)
after endocytosis, the release of the viral genome from
endosomes into the cytoplasm by disruption of the endoso-
mal membrane, in the case ofmembrane-free viruses (such as
adenoviruses), or the fusion of the viral membrane with
endosomal membranes, in the case of enveloped viruses
(such as influenza virus). Viruses that enter via this endoso-
mal route are thought to exploit the endosomal acidification
process, which specifically activates their endosomolytic or
fusogenic protein domains. This has been demonstrated in
detail for the influenza viruses (9).
We, and others (10, 11), have used the cellular mechanism
of receptor-mediated endocytosis of macromolecules or vi-
ruses, employing ligands such as transferrin (12-14) or viral
proteins (15), for the import ofDNA molecules into cells. The
key steps have been the conjugation ofthe ligand for a certain
cell receptor to a DNA-binding moiety, such as a polycation
or an intercalating compound, and the formation of com-
plexes of this conjugate with the DNA to be delivered. We
have demonstrated that polylysine conjugates condense the
DNA into small structures with a size of 80-100 nm (14),
which approximate the size of many viruses. These DNA
complexes, however, still lack the second important function
of viral entry-namely, a mechanism for escape from endo-
somes, which is a limiting step for reporter gene expression
during receptor-mediated gene delivery (16).
In the present communication, we describe the inclusion of
fusogenic peptides derived from the N-terminal sequence of
the influenza virus hemagglutinin subunit HA-2 as part of the
DNA complexes and the resulting augmentation of gene
transfer to cultured cells. These DNA complexes, containing
polylysine as the nucleic acid packaging module,
polylysine-modified transferrin as the receptor binding mod-
ule, and polylysine-bound influenza peptides as the endoso-
molytic module, represent a simple model of an artificial
membrane-free virus without replication functions, which
can be used to deliver genes to eukaryotic cells.
MATERIALS AND METHODS
Materials. Human transferrin-poly(L-lysine) conjugates
with an average chain length of 190 lysine residues
(TfpL19OB) or 290 lysine residues (TfpL290) were prepared
as described (17). Nl-undecyl-polylysine (C11pL) was syn-
thesized by reaction of the trifluoroacetate salt of poly-
(L-lysine) (average chain length of 200 lysine monomers,
prepared from hydrobromide salt; Sigma) in a solution of
freshly distilled dioxane/water, 4:1 (vol/vol), with undecanal
(Sigma) and reduction of the resulting aldiminium salts to the
corresponding amines with sodium cyanoborohydride. Ac-
cording toNMR analysis, polylysine was modified with about
50 undecyl groups per molecule.
Peptide Synthesis. Peptide 1 with the sequence Gly-Leu-
Phe-Glu-Ala-lle-Ala-Gly-Phe-lle-Glu-Asn-Gly-Trp-Glu-Gly-
Met-Ile-Asp-Gly-Gly-Gly-Cys was synthesized by the fluoren-
9-ylmethoxycarbonyl (Fmoc) procedure (18) using an Applied
Biosystems 431A peptide synthesizer. The crude peptide
dissolved in 3.5 ml of20mM aqueous ammonium bicarbonate
containing 300 ,ll of 25% ammonia per liter (buffer A) was
purified by ion-exchange chromatography (Mono Q column;
Abbreviations: TfpL19OB and TfpL290, transferrin-poly(L-lysine)
conjugates with an average chain length of 190 and 290 lysine
residues, respectively; C11pL, Ne-undecyl-polylysine; pLys300,
polylysine with an average chain length of 300 lysine residues;
InflulpL, Influ2pL, and Influ3pL, conjugates of polylysine with
influenza peptide 1, peptide 2, and peptide 3, respectively; FCS, fetal
calf serum.
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Pharmacia; gradient elution with 0-100%o buffer B in buffer A;
buffer B = buffer A plus 3 M NaCl; the peptide was eluted at
1 M NaCl) and subsequently by reverse-phase HPLC
(Bio-Rad Hi-Pore RP-304 column; gradient elution with
50-100%o buffer C in buffer A; buffer C = buffer A in 98%
methanol) to yield pure peptide 1 in the cysteine-protected
form. A time-of-flight mass spectrum (19) obtained with a Bio
Ion 252Cf PD-MS instrument (Uppsala, Sweden) showed a
mass of 2401 (M + H+). Peptide 1 in the free mercapto form
was obtained by treatment with thioanisol/ethanedithiol/
trifluoroacetic acid/trifluoromethanesulfonic acid, 2:1:40:3
(vol/vol).
Peptide 2 (with Glu-4 of peptide 1 changed to Gly) was
synthesized in a manner analogous to peptide 1. A control
peptide 3 with the same amino acid composition as peptide 1,
but with the scrambled sequence Phe-Leu-Gly-Ile-Ala-Glu-
Ala-Ile-Asp-Ile-Gly-Asn-Gly-Trp-Glu-Gly-Met-Glu-Phe-
Gly-Gly-Gly-Cys, was also synthesized.
Conjugation of Influenza Peptides to Polylysine. Polylysine
with an average chain length of 300 lysine residues (pLys300;
67 nmol, modified with 0.3 pumol of 2-pyridyldithiopropionate
linker, prepared as described in ref. 12) in 2.2 ml of 2 M
guanidinium hydrochloride/20 mM ammonium bicarbonate,
pH 8.2, was allowed to react overnight at room temperature
with 0.35 pumol of peptide 1 in the thiol form. The mixture was
dialyzed against 0.5 M guanidinium hydrochloride/20 mM
Hepes, pH 7.3. Conjugates were isolated by cation-exchange
chromatography on a Mono S column (Pharmacia) using a
gradient from 0%6 to 100%o buffer E in buffer D (buffer D = 0.5
M guanidinium hydrochloride, 20 mM Hepes, pH 7.3; buffer
E = 3 M guanidinium hydrochloride/20 mM Hepes, pH 7.3).
The material eluting with 1.5 M guanidinium hydrochloride
was pooled and dialyzed against HBS (150 mM NaCl/20 mM
Hepes, pH 7.3). According to a ninhydrin assay and absorp-
tion at 280 nm, influenza peptide 1-polylysine conjugates
(InflulpL) with a molar ratio of peptide to pLys300 of 4:1 were
obtained. The coupling of the influenza peptide 2 or peptide
3 to polylysine was performed as described above. Influenza
peptide 2-polylysine conjugates (Influ2pL) with a molar ratio
of peptide to pLys30w of 1:1, 3:1, or 8:1 were synthesized.
Liposome Leakage Assays. Liposomes of phosphatidylcho-
line (Avanti Polar Lipids) containing 100 mM calcein (adjust-
ed to pH 7.3 by addition of sodium hydroxide) were prepared
by using the reverse-phase evaporation method (20, 21). The
liposome mixture was extruded several times through a
Nucleopore polycarbonate membrane (100 nm). The lipo-
somes were separated from nonincorporated material by gel
filtration (Sephadex G-50; Pharmacia). The lipid phosphorus
of the resulting liposome solution was determined by using
the method of Bartlett (22). Leakage of liposomal contents in
the presence of various lysogenic peptides or derivatives was
measured by the release of entrapped calcein (23). The
calcein fluorescence was measured at 515 nm (excitation at
490 nm). Aliquots of the above liposome solution were
diluted 100-fold (final concentration, 25,uM lipid) with 0.15 M
sodium chloride/citrate buffers of the appropriate pH
(4.5-7.3). To 1 ml of these solutions was added 0.5 ,g of
peptide (t-butyl-protected form at 0.2 ,g/,u in HBS), while
mixing with a gentle stream of argon (final concentration, 0.2
AM peptide). The values corresponding to 100% leakage weredetermined by complete lysis of liposomes after the addition
of 5 ,ul of 10% Triton X-100 (Fluka).
Cells, DNA Complex Formation, and Transfections. K562
cells were grown in suspension in RPMI 1640 medium
(GIBCO/BRL) containing 10% fetal calf serum (FCS), pen-
icillin at 100 units/ml, streptomycin at 100 pg/ml, and 2 mM
glutamine. At 20 hr before transfection, the cells were placed
in fresh medium containing 50 ,uM desferrioxamine (13).
Transfections were performed with 5 x 105 cells suspended
in 2 ml of fresh medium containing 10%1 FCS (plus 50 tkM
desferrioxamine). HeLa cells were grown in 6-cm plates in
Dulbecco's modified Eagle's medium plus 5% FCS, antibi-
otics, and glutamine. Transfections were performed at a
density of 3 x 105 cells per plate with 1 ml of fresh medium
containing 2% FCS. For 3-galactosidase gene transfer ex-
periments, HeLa cells were grown in 3-cm culture dishes on
coverslips (3 x 104 cells per dish). BNL CL.2 cells were
grown in 6-cm plates in high-glucose Dulbecco's modified
Eagle's medium (0.4% glucose) supplemented with 10%o FCS,
antibiotics, and glutamine. Approximately 1 hr before the
transfection, the cells were cultured in 1 ml of fresh medium
containing 2% FCS.
DNA complexes were prepared by mixing a solution of 6
pMg of plasmid DNA in 330 ,ul ofHBS with a solution of 12 Ig
of TfpL19OB (or 8 pg of TfpL290) in 160 .ul of HBS. DNA
combination complexes containing transferrin-polylysine
and influenza peptide-polylysine conjugates were prepared
by first mixing 6 ,ug of plasmid DNA in 160 pli of HBS with
6 ,ug of TfpL19OB (or 4 pkg of TfpL290) in 160 pl1 ofHBS and,
after 15-30 min at room temperature, subsequent mixing with
the influenza peptide-polylysine conjugate in 160 td of HBS.
Addition of the DNA complexes to the cells and further
treatment of the cultures is described in the figure legends.
Cells were harvested and assayed for luciferase activity as
described (12, 15). f-Galactosidase activity was assayed as
described in refs. 24 and 25.
RESULTS
Synthesis and Properties of Membrane-Disruptive
Peptide-Polylysine Conjugates. We synthesized two peptides
containing the sequences of the 20 N-terminal residues of
HA-2: peptide 1 with a substitution of glycine for glutamic
acid at position 4 from a mutant sequence (26) and peptide 2
with a wild-type sequence, similar to that described in ref. 27,
but with C-terminal extensions containing a terminal cysteine
as a handle for conjugation. The membrane-disrupting prop-
erties of these peptides were determined by a liposome
leakage assay, which measures the release of calcein, a
fluorescent dye, from phosphatidylcholine liposomes (Fig.
1A). Peptide 1 showed leakage activity only at acidic pH,
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FIG. 1. Liposome leakage mediated by influenza peptides,
peptide-polylysine conjugates, or peptide-polylysine conjugates
complexed to DNA. Leakage activity was determined by mixing the
compound with a solution of calcein-loaded liposomes and measuring
the fluorescence after a 20-min incubation at room temperature (see
Materials and Methods). (A) o, 0.5 j&g of peptide 1; *, 0.5 Mg of
peptide 2; O, 0.5 Mg of peptide 3. (B) o, InflulpL (0.5 Ag of peptide
1 linked to 3.3 Mg of polylysine); *, Influ3pL (0.5 Mg of peptide 3
linked to 3 jg of polylysine); *, InflulpL conjugates (0.5 jg)
complexed with plasmid DNA (1 Mg) and TfpL290 (0.7 Mg); A, C11pL
(3.3 MIg); &, unmodified polylysine (3.3 Mig).
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whereas peptide 2, derived from the wild-type sequence, had
some residual leakage activity at neutral pH. These leakage
data are consistent with liposome fusion data of analogous
peptides (27). We have observed an increased tendency ofthe
wild-type sequence (peptide 2) to lose some of the leakage
activity upon storage at 4TC in physiological buffer at pH 7.3,
which may be explained by partial self-aggregation. In con-
trast, the acidic mutant peptide 1 does not display this
behavior.
The peptides were linked to polylysine by reacting the
cysteine mercapto groups with pyridyldithio-modified poly-
lysines to yield disulfide-conjugated peptide-polylysine de-
rivatives. The conjugates InflulpL, derived from peptide 1,
and Influ2pL, derived from peptide 2, with one to eight
influenza peptides per polylysine chain were prepared (see
Materials and Methods). In the liposome leakage assay, the
peptide conjugate InflulpL had a higher activity than uncon-
jugated peptide 1 (Fig. 1B). The conjugate InflulpL still
showed a pH dependence but, in contrast to free peptide 1,
had significant activity at neutral pH. Unmodified polylysine
had no leakage activity; polylysine conjugated to the control
peptide 3 (Influ3pL) had very low activity. A lipophilic
polylysine, modified with undecyl groups (C11pL), showed a
moderate, pH-independent activity in this assay (Fig. 1B).
Complexing the peptide-polylysine conjugate with DNA
reduced the leakage activity again, in particular the activity
at neutral pH (Fig. 1B).
Luciferase Gene Delivery by DNA Combination Complexes
Containing Transferrin and Membrane-Disruptive Peptides.
Combination complexes consisting of plasmid DNA encod-
ing the Photinus pyralis luciferase (pCMVL) as a reporter
gene, transferrin-polylysine, and peptide-polylysine conju-
gates were prepared by adding transferrin-polylysine to
DNA to neutralize half of the DNA charge; the remainder of
the charge was then saturated by addition of influenza
peptide-polylysine conjugate. The standard transferrinfec-
tion to the erythroleukemic cell line K562 requires the
presence of chloroquine (13). In the absence of this lysoso-
matropic agent, no subsequent gene expression occurred
with either transferrin-polylysine-complexed DNA or
polylysine-complexed DNA (Fig. 2). The combination com-
plexes containing the influenza peptide conjugate, however,
particularly if transferrin-polylysine was included as the
receptor-binding component, showed high luciferase expres-
sion (Fig. 2). Neither unconjugated peptide (data not shown)
nor polylysine modified with lipophilic undecyl residues (Fig.
2) can substitute for the polylysine-conjugated peptide in
mediating gene expression. This indicates that the amphi-
pathic character of the influenza peptide conjugates cannot
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be replaced by lipophilic modifications, although these mod-
ifications allow polylysine to disrupt membranes to a mod-
erate degree, albeit in a pH-independent manner (see Fig. 1).
Similar gene transfer experiments were performed with
HeLa cells that, even in the presence of chloroquine, showed
only a moderate transferrinfection efficiency. The data
shown in Fig. 3 demonstrate the importance of including the
peptide conjugate in the DNA-transferrin-polylysine com-
plex. Incorporation of peptide-polylysine conjugates into
complexes, where only half of the plasmid DNA is com-
plexed with transferrin-polylysine [TfpL(4,gg)+Influ1pL],
resulted in an over 100-fold improvement over TfpL-DNA
complexes alone. When the DNA was first completely sat-
urated with transferrin conjugates [TfpL(8,ug)+Influ1pL],
the additional free lysogenic conjugate (which cannot bind
the DNA) still had some effect, but a much lower one than if
the peptide was part of the complex. Free peptides 1 and 2
had no promoting effect on gene transfer, but clearly showed
toxic effects at higher concentrations. In the special case of
HeLa cells, unmodified polylysine exerted a considerable,
but less pronounced, enhancement of the transferrin-
polylysine-mediated gene transfer than the peptide-
polylysine conjugates (see Fig. 6). This unspecific polylysine
effect in HeLa cells was blocked by raising the serum content
of the medium to 10-20o (data not shown).
Different combination complexes consisting of DNA,
transferrin-polylysine, and optimum amounts of the peptide
conjugate InflulpL or one of the three Influ2pL conjugates
with different peptide-to-polylysine ratios were tested for
gene transfer efficiency to the murine hepatocytic cell line
BNL CL.2 (Fig. 4A). A clear correlation between the content
of peptide in the conjugate and the gene transfer augmenting
activity was observed. Combination complexes containing
conjugates with a high molar ratio of membrane-disruptive
peptide to polylysine [Influ2pL(8:1) or InflulpL(4:1)] pro-
duced up to a 1000-fold increase in luciferase gene expres-
sion. The use of conjugates with a low content of peptide
[Influ2pL(1:1)], of unmodified polylysine, or of Influ3pL
(data not shown) was far less effective in these cells. These
findings also correlate with the leakage activities of the
conjugates in the liposome assay (Fig. 4B). The conjugates of
influenza peptides 1 and 2 showed comparable augmentation
of the gene transfer to hepatocytes.
A comparison of several transferrin-polylysine-mediated
gene transfer procedures is shown in Fig. 5. The standard
transferrinfection to BNL CL.2 cells using DNA-transferrin-
polylysine complexes resulted in limited gene expression in
both the absence and presence of chloroquine (Fig. 5).
Inclusion of the peptide conjugate InflulpL considerably
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FIG. 2. Transfection ofK562 cells. Complexes of6 Ag ofpCMVL
DNA and the indicated amounts of TfpL19OB conjugate (TfpL) [or
pLys3oo (pLys)] InflulpL, or C11pL were added to K562 cells (see
Materials and Methods). The cells were incubated at 37°C for 24 hr
and then harvested for the luciferase assay. In this figure and Figs.
3-5, the values shown represent the total luciferase activity of the
transfected cells.
FIG. 3. Transfection of HeLa cells. Complexes containing 6 pg
ofpCMVLDNA and the indicated amounts ofthe TfpL290 conjugate
(TfpL) [or pLys300 (pLys)] and InflulpL conjugate were prepared
and added to the cells as described in Materials and Methods. The
cells were incubated at 37°C for 2 hr, then 2.5 ml of medium
containing 10%6 FCS was added. After 24 hr the cells were harvested
for the luciferase assay.
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FIG. 4. Transfection efficiencies of different influenza peptide
conjugates. (A) Complexes of6 ug ofpCMVL DNA, 4 Ag ofTfpL290
conjugate (TfpL), and 20 ,ug ofInflu2pL conjugates with molar ratios
of peptide to polylysine of 1:1, 3:1, and 8:1 or, for comparison, 20 Ag
of pLys3oo (pLys) or 20 pg ofconjugate InflulpL were added to BNL
CL.2 cells (as described in Materials and Methods). The cells were
incubated at 370C for 4 hr, then 2 ml of medium containing 18% FCS
was added. After 24 hr, the cells were harvested for the luciferase
assay. (B) Liposome leakage activity of Influ2pL conjugates (equiv-
alent to 2.5 ,ug of polylysine) at pH 5.0, performed as described in
Materials and Methods.
increased gene expression. In combination with chloroquine,
the gene expression was further enhanced (see Discussion).
(-Galactosidase Gene Delivery to HeLa Cells and Detection
of Expression at the Cellular Level. DNA complexes contain-
ing a 3galactosidase reporter gene were used for delivery to
HeLa cells, and the subsequent gene expression was visu-
alized on the cellular level (Fig. 6). Using transferrin-
polylysine-complexed DNA, only a few cells (-1 in 1000)
expressed f3galactosidase (data not shown). Combination
complexes, additionally including the influenza peptide con-
jugate InflulpL, showed a strong expression of 3galacto-
sidase in 3-10% ofthe cells (Fig. 6A). The control experiment
with complexes containing transferrin-polylysine conjugates
together with comparably high amounts of unmodified poly-
lysine resulted in expression in =0.5% of the cells (see Fig.
6B). Cells transfected with the combination complexes rep-
licated normally and transferred the introduced gene equally
to their daughter cells, leading to groups of predominantly
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FIG. 5. Transfection of murine hepatocytes. The effect of chlo-
roquine (chloro), InflulpL, or the combination of both agents on
transferrin-polylysine (TfpL)-mediated luciferase gene delivery (6
Ag of pCMVL plasmid, 24 hr) to BNL CL.2 hepatocytes is shown.
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FIG. 6. In situ demonstration of frgalactosidase expression in
HeLa cells. Transfections using pCMV-(-gal DNA (28) complexes
were carried out as described in Fig. 3. After 48 hr, staining reactions
were performed for 1 hr (see Materials and Methods). (A) HeLa cells
transfected with 6 jig of pCMV-3-gal complexed with 4 /lg of
TfpL290 and 20 pg of InflulpL. Approximately 3-10% of the cells
show a strongly positive reaction for fgalactosidase. (B) HeLa cells
transfected with 6 sAg of pCMV-3gal complexed with 4 ug of
TfpL290 and 10 jkg of polylysine. (fgalactosidase expression is
observed in -0.5% of the cells.)
four expressing cells 48 hr after transfection, which correlates
with a progression through two cell cycles.
DISCUSSION
When complexes of the transferrin-polylysine conjugate (12,
17) and DNA are incubated with cells, the complexes bind to
the transferrin receptors and are internalized by the cells,
leading to expression ofgenes contained within the DNA (13,
29). In order to obtain high levels of gene expression,
measures have to be taken to protect the DNA from degra-
dation in lysosomes and/or release it from intracellular
vesicles into the cytoplasmic compartment and finally into
the nucleus of the cell (15). The approach described here
makes use of the efficient mechanisms that many viruses (for
instance, adenovirus and influenza virus) employ for the
release from endosomes. Instead of using whole free viruses,
we have taken synthetic fusogenic peptides derived from an
influenza virus envelope protein and linked them to a com-
plex containing DNA, transferrin, and polylysine, with the
hope that the activity, which in its natural context causes
fusion with the endosomal membrane, may disrupt endo-
somes in the context of our artificial complexes. In the case
of influenza virus, the fusion activity has been extensively
studied (30). The factor responsible for fusion of viral and
endosomal membranes is the viral membrane glycoprotein
hemagglutinin, a homotrimer, each monomer of which con-
sists of two polypeptides, HA-1 and HA-2, connected
through a disulfide bond (31). The membrane fusion activity
is triggered by an acid-induced change, which exposes the
highly conserved hydrophobic N-terminal region of the HA-2
subunit, allowing it to interact with the endosomal mem-
brane. Synthetic peptides corresponding to the N terminus of
influenza HA-2 are able to fuse artificial lipid membranes and
cause leakage of aqueous liposomal contents (27, 32). Such
peptides were shown to increase their a-helicity when inter-
acting with lipid membranes (27, 32). Protonation of the
acidic residues (glutamic acid at positions 11 and 15 and
aspartic acid at position 19, which align on a predicted t-helix
and exert charge repulsions at neutral pH) is expected to
promote transition to a helical structure concomitant with
membrane binding and destabilization. Peptides containing
the sequences of the N terminus of HA-2 and polylysine
conjugates thereof show pH-dependent leakage activities in
a liposome assay (Fig. 1). Peptide 1 has leakage activity only
at low pH. This is consistent with the model that the
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additional glutamic acid at position 4 would further destabi-
lize an at-helix at neutral pH.
Combination complexes consisting of plasmid DNA en-
coding luciferase or f3-galactosidase as reporter genes,
transferrin-polylysine, and membrane-disruptive peptide-
polylysine conjugates were used for gene transfer to cell lines
ofthe erythroid lineage (K562 cells) or epithelial lineage (HeLa
cells and BNL CL.2 hepatocytes) as well as NIH 3T3 fibro-
blasts (data not shown). The influenza peptide conjugates
considerably augmented the transferrin-polylysine-mediated
gene delivery. By using different peptide-polylysine conju-
gates, a close correlation between the content of peptide
within a polylysine conjugate, liposome leakage activity, and
augmentation of gene expression mediated by a particular
peptide conjugate was found (Fig. 4). The polylysine conju-
gates of the two different peptide sequences show no signifi-
cant differences in the gene transfer-enhancing activities.
Inclusion of chloroquine shows a promoting effect on the
gene-transfer complexes, suggesting that the entry occurs via
an endocytic pathway (Fig. 5). The synergistic effect of
chloroquine (which raises the pH of internal vesicles and
therefore should reduce the peptide's pH-dependent leakage
activity) was unexpected but can be explained by a protection
of the conjugates from lysosomal degradation, by osmotic
destabilization of the endocytic vesicles by internal accumu-
lation of chloroquine (25, 33), and/or by the observation that
the influenza peptide conjugates display some residual leak-
age activity at neutral pH.
Expression of a galactosidase reporter gene in HeLa cells
(Fig. 6) demonstrates that the influenza peptide conjugates
facilitate transferrinfection up to a level of high expression in
about 5-10%6 of all cells. This frequency is low compared to
the transferrinfection performed in the presence of free or
DNA-bound defective adenoviruses (34, 35) where frequen-
cies of 290%o are observed. However, with the use of whole
virus, some cytopathic effects on the transfected cell popu-
lation can be observed (34). With the DNA complexes
containing the membrane-disruptive peptides, no toxic ef-
fects have been found.
Our transport complexes can be likened to artificial viruses
that mimic the viral transfer ofgenes into cells but are devoid
of all cytopathic and replicative functions of natural viruses.
Once higher efficiencies ofgene transfer have been obtained,
such artificial viral complexes may become the method of
choice. The present report may be considered as a first step
toward this goal. The model complexes described here con-
tain amphipathic peptides as the minimal functional unit for
specific membrane disruption but lack the ordered architec-
ture of viral surfaces thought to mediate optimal entry.
We appreciate the helpful discussions and the critical reading of
this manuscript by Dr. Martin Nicklin. We also thank Karl Mechtler
and Helen Kirlappos for technical assistance. We are grateful to Dr.
Horst Ahorn for the help in preparing time-of-flight mass spectra.
1. Ballay, A., Levrero, M., Buendia, M., Tiollais, P. & Perricau-
det, M. (1985) EMBO J. 4, 3861-3865.
2. Berkner, K. L. (1988) BioTechniques 6, 616-629.
3. Keller, G., Paige, C., Gilboa, E. & Wagner, E. F. (1985) Nature
(London) 318, 149-154.
4. Armentano, D., Yu, S., Kantoff, P., Anderson, W. F. &
Gilboa, E. (1987) J. Virol. 61, 1647-1650.
5. Piccini, A., Perkus, M. E. & Paoletti, E. (1987) Methods
Enzymol. 153, 545-562.
6. Falkner, F. G. & Moss, B. (1988) J. Virol. 62, 1849-1854.
7. Hermonat, P. & Muzyczka, N. (1984) Proc. Natl. Acad. Sci.
USA 81, 6466-6470.
8. Samulski, R., Chang, L. & Shenk, T. (1989) J. Virol. 63,
3822-3828.
9. Wiley, D. C. & Skehel, J. J. (1987) Annu. Rev. Biochem. 56,
365-394.
10. Wu, C., Wilson, J. & Wu, G. (1989) J. Biol. Chem. 264,
16985-16987.
11. Huckett, B., Ariatti, M. & Hawtrey, A. 0. (1990) Biochem.
Pharmacol. 40, 253-263.
12. Wagner, E., Zenke, M., Cotten, M., Beug, H. & Birnstiel, M.
L. (1990) Proc. Natl. Acad. Sci. USA 87, 3410-3414.
13. Cotten, M., Laengle-Rouault, F., Kirlappos, H., Wagner, E.,
Mechtler, K., Zenke, M., Beug, H. & Birnstiel, M. L. (1990)
Proc. Natl. Acad. Sci. USA 87,4033-4037.
14. Wagner, E., Cotten, M., Foisner, R. & Birnstiel, M. L. (1991)
Proc. Natl. Acad. Sci. USA 88, 4255-4259.
15. Cotten, M., Wagner, E. & Birnstiel, M. L. (1992) Methods
Enzymol., in press.
16. Curiel, D. T., Agarwal, S., Wagner, E. & Cotten, M. (1991)
Proc. Natl. Acad. Sci. USA 88, 8850-854.
17. Wagner, E., Cotten, M., Mechtler, K., Kirlappos, H. & Birn-
stiel, M. L. (1991) Bioconjugate Chem. 2, 226-231.
18. Atherton, E., Gait, M. J., Sheppard, R. C. & Williams, B. J.
(1979) Bioorg. Chem. 8, 351-370.
19. Macfarlane, R. D., Vemura, D., Veda, K. & Hirata, Y. (1980)
J. Am. Chem. Soc. 102, 875.
20. Szoka, F. & Papahadjopoulos, D. (1978) Proc. Natl. Acad. Sci.
USA-75, 4194-4198.
21. Straubinger, R. M. & Papahadjopoulos, D. (1983) Methods
Enzymol. 101, 512-527.
22. Bartlett, G. R. (1959) J. Biol. Chem. 234, 466.
23. Bondeson, J., Wijkander, J. & Sundler, R. (1984) Biochim.
Biophys. Acta 777, 21-27.
24. Lim, K. & Chae, C.-B. (1989) BioTechniques 7, 576-579.
25. Zatloukal, K., Wagner, E., Cotten, M., Phillips, S., Plank, C.,
Steinlein, P., Curiel, D. & Birnstiel, M. L. (1992) Ann. N. Y.
Acad. Sci., in press.
26. Gething, M.-J., Doms, R. W., York, D. & White, J. (1986) J.
Cell Biol. 102, 11-23.
27. Wharton, S. A., Martin, S. R., Ruigrok, R. W. H., Skehel, J.
J. & Wiley, D. C. (1988) J. Gen. Virol. 69, 1847-1857.
28. MacGregor, G. R. & Caskey, C. T. (1989) Nucleic Acids Res.
17, 2365.
29. Zenke, M., Steinlein, P., Wagner, E., Cotten, M., Beug, H. &
Birnstiel, M. L. (1990) Proc. Natl. Acad. Sci. USA 87,
3655-3659.
30. Wiley, D. C. & Skehel, J. J. (1987) Annu. Rev. Biochem. 56,
365-394.
31. Wiley, D. C., Skehel, J. J. & Waterfield, M. D. (1977) Virology
79, 446-48.
32. Lear, J. D. & Grado, W. F. (1987) J. Biol. Chem. 262,
6500-6505.
33. Corley Cain, C., Sipe, D. M. & Murphy, R. F. (1989) Proc.
Natl. Acad. Sci. USA 86, 544-548.
34. Cotten, M., Wagner, E., Zatloukal, K., Phillips, S., Curiel, D.
T. & Birnstiel, M. L. (1992) Proc. Natl. Acad. Sci. USA 89,
6094-6098.
35. Wagner, E., Cotten, M., Zatloukal, K., Curiel, D. & Birnstiel,
M. L. (1992). Proc. Natl. Acad. Sci. USA 89, 6099-6103.
Proc. Natl. Acad Sci. USA 89 (1992)
